About

Imatinib, the active component of Knilonat, is a tyrosine kinase inhibitor primarily used in the treatment of various cancers, particularly chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It works by selectively inhibiting the Bcr-Abl tyrosine kinase, which is a hallmark of CML, and other receptor tyrosine kinases such as KIT and PDGFRA, which are implicated in GIST. This targeted action prevents the proliferation of cancer cells and induces apoptosis, thereby controlling disease progression.

Its introduction revolutionized the treatment landscape for CML, transforming a previously fatal disease into a manageable chronic condition for many patients. Imatinib's efficacy stems from its ability to block the signaling pathways essential for the survival and growth of these specific cancer cells, offering a more precise and less toxic approach compared to conventional chemotherapy.

Uses

Treatment of chronic myeloid leukemia (CML).
Management of gastrointestinal stromal tumors (GIST).
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Management of myelodysplastic/myeloproliferative diseases (MDS/MPD).

Directions For Use

Take this capsule orally with a meal and a large glass of water to minimize gastrointestinal irritation. Follow your doctor's prescribed dosage.

Benefits

Highly effective in achieving remission in CML.
Significantly improves survival rates in CML and GIST.
Targets specific cancer-driving enzymes.
Reduces tumor burden and disease progression.
Offers a more tolerable treatment profile than traditional chemotherapy.
Available in oral form for convenient administration.

Side Effects

Nausea
Vomiting
Diarrhea
Muscle cramps
Fluid retention (edema)
Fatigue
Skin rash
Abdominal pain
Headache
Myelosuppression (low blood counts)
Liver enzyme elevation
Periorbital edema

Safety Measures

Alcohol - Avoid or limit alcohol consumption, as it may increase the risk of liver toxicity, a potential side effect of imatinib.
Pregnancy - Imatinib is not recommended during pregnancy due to potential teratogenic effects. Women of childbearing potential should use effective contraception.
Breastfeeding - Breastfeeding is contraindicated during imatinib treatment and for a period after the last dose, as the drug is excreted into breast milk.
Liver - Use with caution in patients with hepatic impairment. Regular monitoring of liver function tests is essential, and dose adjustments may be required.
Kidney - No specific dose adjustment is typically needed for mild to moderate renal impairment, but close monitoring is advised in severe cases.
Lung - Monitor for new or worsening respiratory symptoms, as pleural effusion or interstitial lung disease can occur, though rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.

Shipping & Location